SGLT2 Inhibitors - Medications That Lower Blood Glucose By Inhibiting Glucose Reabsorption In The Kidneys - Regner Health Solutions

By blocking the SGLT2 protein, which is responsible for the reabsorption of glucose in the kidneys, these medications promote the elimination of excess glucose from the body. As a result, the blood glucose levels decrease and remain more stable. In addition to their direct impact on blood glucose levels, SGLT2 inhibitors have been associated with weight loss in individuals. When glucose is excreted through urine instead of reabsorbed, the body experiences a caloric loss. This caloric loss can reduce weight, especially in overweight or obese individuals. Furthermore, SGLT2 inhibitors have been shown to benefit body composition and fat distribution. Research suggests these medications can reduce visceral adiposity, which refers to the fat stored around vital organs. By targeting this harmful type of fat, SGLT2 inhibitors may contribute to overall weight management and improve metabolic health. Learn more about SGLT2 inhibitors and other services we offer: regnerhealthsolutions.com/sglt2-inhibitors/
from Flickr https://flic.kr/p/2pKM3Xa
via https://regnerhealthsolutions.com/
Comments
Post a Comment